MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $41.20 (77.97% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetActions
5/31/2016Credit SuisseDowngradeOutperform -> Neutral$33.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016Citigroup Inc.Boost Price TargetBuy$29.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyLower Price Target$71.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Goldman SachsDowngradeBuy -> Neutral$65.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Cowen and CompanyReiterated RatingBuy$65.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.90)($0.82)$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2013($0.72)($1.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.13)($1.13)($1.13)
Q2 20171($0.93)($0.93)($0.93)
Q3 20171($0.82)($0.82)($0.82)
Q4 20171($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)
Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
DateHeadline
06/24/16 06:01 PMPortola Pharmaceuticals Incorporated (NASDAQ:PTLA) Shorted Shares Increased 2.99% After Market Selling - Press Telegraph
06/22/16 05:56 PMEarnings Review: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - iStreetWire
06/22/16 03:20 PMPORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 05:45 PMCommit To Purchase Portola Pharmaceuticals At $17.50, Earn 19.8% Annualized Using Options
06/20/16 02:06 PMETF’s with exposure to Portola Pharmaceuticals, Inc. : June 20, 2016 -
06/17/16 07:22 AMPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : June 17, 2016 -
06/10/16 06:16 PMTrend Of Rating Given To Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Investor Newswire
06/06/16 09:41 AMInvestors Focused Movers: Depomed, Inc. (NASDAQ:DEPO) , Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Street Updates
06/05/16 05:57 PMHow Analysts Rated Portola Pharmaceuticals Inc (NASDAQ:PTLA) Last Week? - HNN
06/02/16 09:00 AMStrong Sell Calls Count For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0 - Investor Newswire - Strong Sell Calls Count For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0Investor NewswireAnalyst score was 1.17. A quarter ago, the mean score was 1.17 and 0 were Strong Sell recommendations. Strong Buy calls were 2, the buy calls were 1 and sell calls on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were 0. The count of Hold ratings was 0.and more »
06/01/16 06:32 PMNews Sentiment For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Investor Newswire - News Sentiment For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)Investor NewswirePortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Average broker stands at 1.17 while it was 1.17 three months ago. The quarterly report of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) can be made public close to 2016-08-02. It is estimated by the recent ...and more »
06/01/16 08:54 AMPortola Pharma (PTLA) Commences Dosing in Cerdulatinib Phase 2a in r/r B-Cell and T-Cell Malignancies - StreetInsider.com - Portola Pharma (PTLA) Commences Dosing in Cerdulatinib Phase 2a in r/r B-Cell and T-Cell MalignanciesStreetInsider.comPortola Pharmaceuticals Inc. (Nasdaq: PTLA) announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have ...
06/01/16 08:54 AMPortola Pharmaceuticals Inc. (PTLA) is Trading Higher on Unusual Volume for May 30 - Equities.com - Portola Pharmaceuticals Inc. (PTLA) is Trading Higher on Unusual Volume for May 30Equities.comPortola Pharmaceuticals Inc. (PTLA) experienced unusually high volume on May. 30, as the stock gained 4.6% to a closing price of $27.50. The stock saw 1.55 million shares trade hands over the course of the day on 9,919 trades. Given that the stock's ...and more »
06/01/16 07:13 AMPortola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating ...
05/31/16 06:17 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) went up 4.60%: The Coca-Cola Company (NYSE:KO), Flushing ... - KC Register - Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) went up 4.60%: The Coca-Cola Company (NYSE:KO), Flushing ...KC RegisterOn 27 May, Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were presented today for the first time in a late-breaking ...and more »
05/31/16 03:23 PMPortola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37 Annual Healthcare ...
05/31/16 09:40 AMStock Review and Earnings Check on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - HNN - Stock Review and Earnings Check on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report quarterly EPS of $-1.33. The company's next earnings report is expected to be ...and more »
05/31/16 09:40 AMLinear Technology Corporation (NASDAQ:LLTC) increased 0.23%: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA ... - KC Register - Linear Technology Corporation (NASDAQ:LLTC) increased 0.23%: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA ...KC RegisterOn 27 May, Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were presented today for the first time in a late-breaking ...
05/31/16 09:39 AMEarnings Overview: Anthem (ANTM), Portola Pharmaceuticals (PTLA) - Beacon Chronicle - Beacon ChronicleEarnings Overview: Anthem (ANTM), Portola Pharmaceuticals (PTLA)Beacon ChronicleLast Trade: The Company closed its last session at $ 130.7 Friday with the gain of 0.84%. The market capitalization of the company is $ 34.66 Billion, with the average Volume of $ 1.76 Million. The stock currently has its 52-Week High range of $ 173.59 ...and more »
05/31/16 09:39 AMPortola Pharmaceuticals Inc (NASDAQ:PTLA): Should You Buy More? - Street Report - Risers & FallersPortola Pharmaceuticals Inc (NASDAQ:PTLA): Should You Buy More?Street Report[The Motley Fool] Portola Pharmaceuticals Inc (NASDAQ:PTLA)(TREND ANALYSIS) After a mixed-bag of trial results for its clinical-stage anticoagulant caused shares to tumble back in March, Portola Pharmaceuticals (NASDAQ:PTLA) has offered up ...Active Biotech Stock News: ZIOPHARM Oncology, Inc. (ZIOP), Portola Pharmaceuticals, Inc. (PTLA)ZergwatchPortola Pharmaceuticals Inc (PTLA) is Downgraded by Credit Suisse to Neutral, Lowers Price Target to $ 30Market DigestMarket Analyst Recent Rating Update: (NASDAQ:IONS),Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)WsNews 4investorsKC Register -The Post -Risers & Fallersall 10 news articles »
05/30/16 10:11 PMActive Stocks Need to Consider- Orexigen Therapeutics (NASDAQ:OREX), Portola Pharmaceuticals (PTLA), Endo ... - Seneca Globe - share market updatesActive Stocks Need to Consider- Orexigen Therapeutics (NASDAQ:OREX), Portola Pharmaceuticals (PTLA), Endo ...Seneca GlobePortola Pharmaceuticals, Inc. (NASDAQ:PTLA) jumps up 4.60% to close at $27.50 as Portola Pharmaceuticals Inc. (PTLA) revealed that full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study ...Stocks in Frontline Trades' Choice: Amgen (NASDAQ:AMGN), Portola Pharmaceuticals (NASDAQ:PTLA), Orexigen ...Street Wise Report (press release) (blog)American Equity Investment Life (NYSE:AEL), Opko Health, Inc. (NYSE:OPK), Fuel Systems Solutions, (NASDAQ:FSYS ...Benchmark Monitorall 9 news articles »
05/29/16 12:10 AMPortola boosted by Betrixaban study results - Shares in Portola Pharmaceuticals Inc (NASDAQ:PTLA) were set to surge on Friday morning after it announced results of a Phase 3 study of Betrixaban. The full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration ...
05/29/16 12:10 AMPortola Pharma (PTLA) Announces Presentation, Publication of Full Phase 3 APEX Study Results in NEJM, ISTH SSC Meeting - Claim your 2-week free trial to StreetInsider Premium here. Portola Pharmaceuticals Inc.® (Nasdaq: PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were ...
05/29/16 12:10 AMPortola Pharmaceuticals Inc (PTLA) Climbs On Phase 3 APEX Study Results - Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares are up 4.75% to $27.54 as of 11:58AM EDT after the company announced full results of its crucial Phase 3 Acute Medically Ill VTE Prevention with Extended Duration Betrixaban (APEX) Study today. The results ...
05/28/16 08:40 AMPortola Pharmaceuticals: Does New Data Get It Back on Track? -
05/27/16 08:00 PMPortola Pharma (PTLA) Announces Presentation, Publication of Full Phase 3 APEX Study Results in NEJM, ISTH SSC ... - StreetInsider.com - Bidness ETCPortola Pharma (PTLA) Announces Presentation, Publication of Full Phase 3 APEX Study Results in NEJM, ISTH SSC ...StreetInsider.comPortola Pharmaceuticals Inc.® (Nasdaq: PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were presented today for the first time in a late-breaking clinical ...Stock Earnings Roundup: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)CWRU ObserverPortola Pharmaceuticals Inc (PTLA) Climbs On Phase 3 APEX Study ResultsBidness ETCPortola Pharmaceuticals, Inc. (NASDAQ:PTLA): Analysts Quick Take on EarningsNews TribuneSonoran Weekly Review -Proactive Investors USA & Canada -FierceBiotechall 10 news articles »
05/27/16 08:54 AMPortola Pharmaceuticals Reveals Full Results Of Final Stage APEX Trial Of Betrixaban -
05/27/16 07:57 AMPortola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting - [at noodls] - --Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016-- --Webcast with APEX Study Executive Committee Members Today at 11 a.m. ET-- MONTPELLIER, France, and SOUTH SAN FRANCISCO, Calif. ...
05/26/16 07:38 PMPortola Pharmaceuticals (NASDAQ:PTLA) To Report June 2016 Results - iStreetWire - Portola Pharmaceuticals (NASDAQ:PTLA) To Report June 2016 ResultsiStreetWirePortola Pharmaceuticals, Inc. (PTLA) retreated -1.37% to reach at the floor price of $26.59 as the company is set to share its next quarterly earnings on August 03, 2016. PTLA stock trades between $26.24 and $27.48 before the earnings release. Let's ...
05/26/16 07:38 PMNotable Stocks Preview: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) , Synthetic Biologics, Inc (NYSEMKT:SYN) , - Street Updates - Notable Stocks Preview: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) , Synthetic Biologics, Inc (NYSEMKT:SYN) ,Street UpdatesOn 5/25/2016, shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) fell -1.37% in trading session and finally closed at $26.59. The company most recent volume stood at 660.2 thousand shares as compared to its average volume of 1.08 million shares.and more »
05/25/16 07:00 PMHold Calls Count For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0 - Investor Newswire - Hold Calls Count For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0Investor NewswirePortola Pharmaceuticals, Inc. (NASDAQ:PTLA) has a total of 2 Strong Buy recommendations and 0 Strong Sell advises as of 2016-05-24. The rating procedure used by Zacks gives scores to firms on a narrow 1-5 scale. A score close to 1-2 band is a Buy call, ...and more »
05/24/16 07:18 PMEarnings Review and Stock Rundown for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Wall Street Hints and News - Earnings Review and Stock Rundown for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Portola Pharmaceuticals, Inc. (NASDAQ ...and more »
05/23/16 12:23 PMPortola Pharma (PTLA) Will Present Full Phase 3 APEX Study Data Set at Annual SSC Meeting - StreetInsider.com - Portola Pharma (PTLA) Will Present Full Phase 3 APEX Study Data Set at Annual SSC MeetingStreetInsider.comPortola Pharmaceuticals Inc.® (Nasdaq: PTLA) announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International ...and more »
05/23/16 07:16 AMPortola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. (NASDAQ:PTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured ...
05/20/16 07:03 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Updated Broker Price Targets - Share Trading News - Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The latest reports which are currently in issue on Friday 20th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/20/16 12:25 AMHow are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies - Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ ...
05/17/16 11:58 PMPortola Pharmaceuticals Inc. (PTLA) Jumps 6.03% on May 16 - Equities.com - Portola Pharmaceuticals Inc. (PTLA) Jumps 6.03% on May 16Equities.comPortola Pharmaceuticals Inc. (PTLA) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 6.03% to $25.16, representing a gain of $1.43 per share. Some 865,726 shares traded hands on 7,587 trades, compared with ...
05/17/16 11:58 PMPortola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock - TheStreet.com - TheStreet.comPortola Pharmaceuticals (PTLA) Is Today's Perilous Reversal StockTheStreet.comCompared to other companies in the Biotechnology industry and the overall market, PORTOLA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500. Looking at the price performance of PTLA's ...Portola Pharmaceuticals Incorporated (NASDAQ:PTLA) Shorts Decreased by 2.97% After Short CoveringFranklin IndependentOrbimed Advisors Llc Decreased Stake in Portola Pharmaceuticals Inc (Put) (NASDAQ:PTLA) by $24.03 Million as ...The PostNext Weeks Broker Price Targets For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)Share Trading Newsall 5 news articles »
05/17/16 06:49 PMShare Recap and Earnings Focus on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Wall Street Hints and News - Share Recap and Earnings Focus on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Portola Pharmaceuticals, Inc.and more »
05/17/16 07:28 AMPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : May 17, 2016 -
05/16/16 05:51 PMETF’s with exposure to Portola Pharmaceuticals, Inc. : May 16, 2016 -
05/14/16 12:04 PMPORTOLA PHARMACEUTICALS INC Financials -
05/13/16 07:33 PMPortola Pharmaceuticals Inc. (PTLA) Jumps 5.75% on May 13 - Equities.com - Portola Pharmaceuticals Inc. (PTLA) Jumps 5.75% on May 13Equities.comPortola Pharmaceuticals Inc. (PTLA) was among the biggest gainers on the Russell 2000 for Friday May 13 as the stock popped 5.75% to $23.73, representing a gain of $1.29 per share. Some 824,703 shares traded hands on 6,533 trades, compared with an ...and more »
05/12/16 08:07 PMStock Earnings Report: Portola Pharmaceuticals Inc (NASDAQ:PTLA) - News Oracle - Stock Earnings Report: Portola Pharmaceuticals Inc (NASDAQ:PTLA)News OracleLast Trade: The Company fell -1.60% and finished at $23.40. The daily volume was measured at 434,992.00 shares. The 52-week high of the share price is $57.96 and the 52-week low is $18.20. The company has a market cap of $1.34 Billion. Its latest ...and more »
05/12/16 12:10 PMPortola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/12/16 01:31 AMConsensus Rating Review for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - B.O.D.Y Confidential - Consensus Rating Review for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1.17 on shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a ...and more »
05/11/16 02:42 PMWhy Portola Pharmaceuticals, Inc. Increased 11.6% in April -
05/10/16 07:49 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Broker Price Targets For The Coming Week - Share Trading News - Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The latest reports which are currently in issue on Tuesday 10th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/10/16 12:25 AMPortola Pharmaceuticals Inc. (PTLA) Jumps 7.66% on May 09 - Equities.com - Portola Pharmaceuticals Inc. (PTLA) Jumps 7.66% on May 09Equities.comPortola Pharmaceuticals Inc. (PTLA) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 7.66% to $23.47, representing a gain of $1.67 per share. Some 1.01 million shares traded hands on 9,717 trades, compared ...and more »
05/06/16 08:20 PMPortola Pharmaceuticals Becomes Oversold (PTLA) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Portola Pharmaceuticals, Inc. (PTLA) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $20.35 per share.
About Portola Pharmaceuticals

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTLA
  • CUSIP:
Key Metrics:
  • Previous Close: $23.15
  • 50 Day Moving Average: $25.41
  • 200 Day Moving Average: $31.14
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.31B
  • Current Quarter EPS Consensus Estimate: $-5.18 EPS
Additional Links:
Portola Pharmaceuticals (NASDAQ:PTLA) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha